Champions Oncology, Inc. (CSBR)
Champions Oncology, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Champions Oncology, Inc. (CSBR) is a Biotechnology company based in US with a market capitalization of $84.7M. Revenue grew 13.5% year-over-year and the company generated $7M in free cash flow. This page tracks CSBR's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 210 employees · IPO Feb 2, 2007
Valuation
Valuation & price
$6.20as of May 17, 2026· -25.3% vs 52w high
18.8
P/E ratio
Latest-FY diluted EPS
22.46
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$84.7M
Market cap
13.5%
Revenue growth (YoY)
50.1%
Gross margin
$7M
Free cash flow (USD)
-$3.7M
Net debt
Net cash position
0.8%
Share dilution
0/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last reported: Jul 16, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
Questions
Frequently asked questions
What is Champions Oncology, Inc.'s market cap?
Champions Oncology, Inc. (CSBR) has a market capitalization of $84.7M.
What is CSBR's P/E ratio?
CSBR trades at a price-to-earnings ratio of 18.8, based on its latest fiscal-year diluted earnings per share and the most recent cached price.
What is CSBR's price-to-book (P/B) ratio?
CSBR trades at 22.46 times book value per share.
When did Champions Oncology, Inc. last report earnings?
CSBR last reported earnings on July 16, 2026; the next date is not yet scheduled.
Are insiders buying CSBR stock?
SEC Form 4 filings show no open-market insider buys at Champions Oncology, Inc. in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.